Anemia treatment by erythropoiesis-stimulating agents during the 6 months before the initiation of hemodialysis: Comparison of darbepoetin alfa and continuous erythropoietin receptor activator

Tadashi Yoshida, Matsuhiko Hayashi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Anemia in chronic kidney disease (CKD) is a risk factor for cardiovascular diseases and is treated by long-acting erythropoiesis-stimulating agents (ESAs). Although the results of previous studies have shown that hemoglobin levels could not be maintained at the initiation of dialysis in CKD patients treated with recombinant human erythropoietin, it remains undetermined whether long-acting ESAs are effective in preventing the progression of anemia at the initiation of dialysis. In the present study, hemoglobin levels in 40 CKD patients treated with darbepoetin alfa (DA) and 15 CKD patients treated with a continuous erythropoietin receptor activator (CERA) were retrospectively compared during the 6 months period before the initiation of dialysis. Results showed that DA and CERA both maintained hemoglobin levels at around 10 g/dL from 6 months to 1 month before dialysis. However, hemoglobin levels at the initiation of dialysis significantly decreased to 9.1 ± 1.2 g/dL in the DA group and to 9.0 ± 1.0 g/dL in the CERA group. Although the total doses of ESAs used during the 6-month period were similar between the two groups, DA-treated CKD patients received subcutaneous injections more frequently than did patients treated with CERA. These results suggest that CKD patients require more intense ESA therapy to prevent a decline in hemoglobin levels at the initiation of dialysis, including those treated with long-acting ESAs. The results also raise the possibility that CERA is more useful than DA for reducing the number of injections during the pre-dialysis period.

Original languageEnglish
Pages (from-to)44-50
Number of pages7
JournalKeio Journal of Medicine
Volume66
Issue number3
DOIs
Publication statusPublished - 2017

Fingerprint

Hematinics
Renal Dialysis
Anemia
Dialysis
Chronic Renal Insufficiency
Hemoglobins
Therapeutics
Subcutaneous Injections
Erythropoietin
continuous erythropoietin receptor activator
Darbepoetin alfa
Cardiovascular Diseases
Injections

Keywords

  • Anemia
  • End-stage kidney disease
  • Erythropoietin
  • Hemodialysis
  • Hemoglobin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{daffba8745814302a75b3f71ccf7aeb2,
title = "Anemia treatment by erythropoiesis-stimulating agents during the 6 months before the initiation of hemodialysis: Comparison of darbepoetin alfa and continuous erythropoietin receptor activator",
abstract = "Anemia in chronic kidney disease (CKD) is a risk factor for cardiovascular diseases and is treated by long-acting erythropoiesis-stimulating agents (ESAs). Although the results of previous studies have shown that hemoglobin levels could not be maintained at the initiation of dialysis in CKD patients treated with recombinant human erythropoietin, it remains undetermined whether long-acting ESAs are effective in preventing the progression of anemia at the initiation of dialysis. In the present study, hemoglobin levels in 40 CKD patients treated with darbepoetin alfa (DA) and 15 CKD patients treated with a continuous erythropoietin receptor activator (CERA) were retrospectively compared during the 6 months period before the initiation of dialysis. Results showed that DA and CERA both maintained hemoglobin levels at around 10 g/dL from 6 months to 1 month before dialysis. However, hemoglobin levels at the initiation of dialysis significantly decreased to 9.1 ± 1.2 g/dL in the DA group and to 9.0 ± 1.0 g/dL in the CERA group. Although the total doses of ESAs used during the 6-month period were similar between the two groups, DA-treated CKD patients received subcutaneous injections more frequently than did patients treated with CERA. These results suggest that CKD patients require more intense ESA therapy to prevent a decline in hemoglobin levels at the initiation of dialysis, including those treated with long-acting ESAs. The results also raise the possibility that CERA is more useful than DA for reducing the number of injections during the pre-dialysis period.",
keywords = "Anemia, End-stage kidney disease, Erythropoietin, Hemodialysis, Hemoglobin",
author = "Tadashi Yoshida and Matsuhiko Hayashi",
year = "2017",
doi = "10.2302/kjm.2016-0009-OA",
language = "English",
volume = "66",
pages = "44--50",
journal = "Keio Journal of Medicine",
issn = "0022-9717",
publisher = "Keio University School of Medicine",
number = "3",

}

TY - JOUR

T1 - Anemia treatment by erythropoiesis-stimulating agents during the 6 months before the initiation of hemodialysis

T2 - Comparison of darbepoetin alfa and continuous erythropoietin receptor activator

AU - Yoshida, Tadashi

AU - Hayashi, Matsuhiko

PY - 2017

Y1 - 2017

N2 - Anemia in chronic kidney disease (CKD) is a risk factor for cardiovascular diseases and is treated by long-acting erythropoiesis-stimulating agents (ESAs). Although the results of previous studies have shown that hemoglobin levels could not be maintained at the initiation of dialysis in CKD patients treated with recombinant human erythropoietin, it remains undetermined whether long-acting ESAs are effective in preventing the progression of anemia at the initiation of dialysis. In the present study, hemoglobin levels in 40 CKD patients treated with darbepoetin alfa (DA) and 15 CKD patients treated with a continuous erythropoietin receptor activator (CERA) were retrospectively compared during the 6 months period before the initiation of dialysis. Results showed that DA and CERA both maintained hemoglobin levels at around 10 g/dL from 6 months to 1 month before dialysis. However, hemoglobin levels at the initiation of dialysis significantly decreased to 9.1 ± 1.2 g/dL in the DA group and to 9.0 ± 1.0 g/dL in the CERA group. Although the total doses of ESAs used during the 6-month period were similar between the two groups, DA-treated CKD patients received subcutaneous injections more frequently than did patients treated with CERA. These results suggest that CKD patients require more intense ESA therapy to prevent a decline in hemoglobin levels at the initiation of dialysis, including those treated with long-acting ESAs. The results also raise the possibility that CERA is more useful than DA for reducing the number of injections during the pre-dialysis period.

AB - Anemia in chronic kidney disease (CKD) is a risk factor for cardiovascular diseases and is treated by long-acting erythropoiesis-stimulating agents (ESAs). Although the results of previous studies have shown that hemoglobin levels could not be maintained at the initiation of dialysis in CKD patients treated with recombinant human erythropoietin, it remains undetermined whether long-acting ESAs are effective in preventing the progression of anemia at the initiation of dialysis. In the present study, hemoglobin levels in 40 CKD patients treated with darbepoetin alfa (DA) and 15 CKD patients treated with a continuous erythropoietin receptor activator (CERA) were retrospectively compared during the 6 months period before the initiation of dialysis. Results showed that DA and CERA both maintained hemoglobin levels at around 10 g/dL from 6 months to 1 month before dialysis. However, hemoglobin levels at the initiation of dialysis significantly decreased to 9.1 ± 1.2 g/dL in the DA group and to 9.0 ± 1.0 g/dL in the CERA group. Although the total doses of ESAs used during the 6-month period were similar between the two groups, DA-treated CKD patients received subcutaneous injections more frequently than did patients treated with CERA. These results suggest that CKD patients require more intense ESA therapy to prevent a decline in hemoglobin levels at the initiation of dialysis, including those treated with long-acting ESAs. The results also raise the possibility that CERA is more useful than DA for reducing the number of injections during the pre-dialysis period.

KW - Anemia

KW - End-stage kidney disease

KW - Erythropoietin

KW - Hemodialysis

KW - Hemoglobin

UR - http://www.scopus.com/inward/record.url?scp=85030099697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030099697&partnerID=8YFLogxK

U2 - 10.2302/kjm.2016-0009-OA

DO - 10.2302/kjm.2016-0009-OA

M3 - Article

C2 - 27990008

AN - SCOPUS:85030099697

VL - 66

SP - 44

EP - 50

JO - Keio Journal of Medicine

JF - Keio Journal of Medicine

SN - 0022-9717

IS - 3

ER -